Advanced search
Publication Cover
mAbs Volume 13, 2021 - Issue 1
Submit an article Journal homepage
5,478
Views
9
CrossRef citations to date
0
Altmetric
Report

Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer

Darren J. Schofielda Antibody Development and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UKView further author information
,
Jennifer Percival-Alwyna Antibody Development and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UKView further author information
,
Mateusz Rytelewskib Discovery Biosciences, Oncology R&D, AstraZeneca, Gaithersburg, MD, USAView further author information
,
John Hoodc Clinical and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UKView further author information
,
Raymond Rothsteinb Discovery Biosciences, Oncology R&D, AstraZeneca, Gaithersburg, MD, USAView further author information
,
Leslie Wetzelb Discovery Biosciences, Oncology R&D, AstraZeneca, Gaithersburg, MD, USAView further author information
,
Kelly McGlincheyd Translational Medicine Department in Oncology R&D, AstraZeneca, Gaithersburg, MD, USAView further author information
,
Grace Adjeie Discovery Biosciences, Oncology R&D, AstraZeneca, Cambridge, UKView further author information
,
Amanda Watkinse Discovery Biosciences, Oncology R&D, AstraZeneca, Cambridge, UKView further author information
,
LeeAnn Machieskyf Analytical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USAView further author information
,
Weimin Chenf Analytical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USAView further author information
,
John Andrewsa Antibody Development and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UKView further author information
,
Maria Grovesa Antibody Development and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UKView further author information
,
Michelle Morrowe Discovery Biosciences, Oncology R&D, AstraZeneca, Cambridge, UKView further author information
,
Ross A. Stewartd Translational Medicine Department in Oncology R&D, AstraZeneca, Gaithersburg, MD, USA;e Discovery Biosciences, Oncology R&D, AstraZeneca, Cambridge, UKView further author information
,
Andrew Leinstere Discovery Biosciences, Oncology R&D, AstraZeneca, Cambridge, UKView further author information
,
Robert W. Wilkinsone Discovery Biosciences, Oncology R&D, AstraZeneca, Cambridge, UKView further author information
,
Scott A. Hammondb Discovery Biosciences, Oncology R&D, AstraZeneca, Gaithersburg, MD, USAView further author information
,
Nadia Luheshie Discovery Biosciences, Oncology R&D, AstraZeneca, Cambridge, UKView further author information
,
Claire Dobsona Antibody Development and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UKView further author information
&
Michael Oberstb Discovery Biosciences, Oncology R&D, AstraZeneca, Gaithersburg, MD, USACorrespondence[email protected]
View further author information
 show all
Article: 1857100 | Received 21 May 2020, Accepted 24 Nov 2020, Published online: 04 Jan 2021

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.